Affymax, Inc. (AFFY) - OTCPK - No Info
  • Jul. 31, 2014, 5:32 PM
    | Jul. 31, 2014, 5:32 PM
  • Apr. 2, 2013, 9:49 AM

    More on Affymax (AFFY -8.1%) Q4: net loss more than doubles to $68.3M as company takes a $45M charge related to the recall of its anti-anemia Omontys drug due to safety concerns. Affymax warns that because of the recall, its ability to continue operations is in doubt. The firm is evaluating various alternatives, including a sale, further restructuring, winding down its ops and bankruptcy proceedings. (PR)

    | Apr. 2, 2013, 9:49 AM
  • Apr. 2, 2013, 6:50 AM
    Affymax (AFFY): Q4 EPS of -$1.85 misses by $1.24. Revenue of $14.8M in-line. (PR)
    | Apr. 2, 2013, 6:50 AM
  • Nov. 9, 2012, 12:13 PM

    Affymax (AFFY +10.2%) trades up after posting a narrow Q3 earnings beat late yesterday. Total revenue increased marginally, by 3% Y/Y, but lower expenses gave a boost to bottom line margins. In its earnings call, the company says that operating expenses are projected to be lower for FY12 as well, now expecting to incur between $130M and $135M in costs, versus previous projections of $135M to $145M. The reduction is primarily driven by lower than expected increases in SG&A expenses due to cost savings. (Transcript)

    | Nov. 9, 2012, 12:13 PM
  • Nov. 8, 2012, 4:03 PM
    Affymax (AFFY): Q3 EPS of -$0.68 beats by $0.02. Revenue of $13.6M (+3% Y/Y) beats by $0.5M. (PR)
    | Nov. 8, 2012, 4:03 PM
  • Nov. 8, 2012, 12:10 AM

    Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP

    | Nov. 8, 2012, 12:10 AM
  • Nov. 7, 2012, 5:35 PM

    Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP

    | Nov. 7, 2012, 5:35 PM
  • May 7, 2012, 4:20 PM
    Affymax (AFFY): Q1 EPS of $0.87. Revenue of $63.2M. Shares -1.7% AH. (PR)
    | May 7, 2012, 4:20 PM | 1 Comment
Company Description
Sector: Healthcare
Industry: Biotechnology
Country: United States